Allarity Therapeutics (NASDAQ:ALLR) Raised to Hold at Wall Street Zen

Allarity Therapeutics (NASDAQ:ALLR) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report released on Saturday.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Monday, April 20th. Ascendiant Capital Markets upped their price objective on Allarity Therapeutics from $9.50 to $9.75 and gave the stock a “buy” rating in a research note on Friday, April 10th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.75.

Allarity Therapeutics Price Performance

NASDAQ ALLR opened at $1.64 on Friday. The business’s fifty day moving average price is $1.35 and its 200-day moving average price is $1.18. The stock has a market capitalization of $26.09 million, a price-to-earnings ratio of -2.28 and a beta of 0.38. Allarity Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.35.

Allarity Therapeutics (NASDAQ:ALLR) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.05. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. Equities research analysts anticipate that Allarity Therapeutics will post -0.96 EPS for the current year.

Institutional Investors Weigh In On Allarity Therapeutics

A number of institutional investors have recently bought and sold shares of ALLR. Private Advisor Group LLC purchased a new stake in Allarity Therapeutics in the 3rd quarter worth $441,000. Renaissance Technologies LLC increased its stake in Allarity Therapeutics by 274.1% in the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after buying an additional 181,426 shares in the last quarter. DRW Securities LLC purchased a new stake in Allarity Therapeutics in the 4th quarter worth $133,000. Capital Advisors Inc. OK purchased a new stake in Allarity Therapeutics in the 4th quarter worth $108,000. Finally, Citadel Advisors LLC purchased a new position in shares of Allarity Therapeutics during the third quarter valued at about $149,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.